Iloprost Teva (Iloprost)

Iloprost is a synthetic prostacyclin analog that activates IP receptors on vascular smooth‑muscle cells, raising cyclic AMP levels. This cascade causes potent vasodilation, inhibits platelet aggregation, and exerts antiproliferative effects on the pulmonary arterial wall, thereby decreasing vascular resistance.

The dosing regimen for Iloprost Teva is individualized. A qualified prescriber determines the infusion rate, duration, and total daily dose based on the patient’s clinical condition, response, and tolerance.

Safety data for Iloprost during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Iloprost Teva, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Iloprost belongs to the prostacyclin analog class, similar to epoprostenol and treprostinil. Compared with epoprostenol, Iloprost has a longer half‑life and can be administered via intermittent intravenous infusion rather than continuous infusion, offering more flexibility but still requiring careful monitoring for hypotension.

Iloprost Teva must be stored refrigerated at 2‑8 °C. Keep the product in its original container, protect it from light, and avoid freezing or shaking the solution. Do not use the product if it has been exposed to temperatures outside this range.

Iloprost Teva is given by intravenous infusion, typically using a controlled infusion pump. The infusion is administered over a set period, often several minutes to an hour, under the supervision of a healthcare professional trained in vascular and pulmonary therapies.

The most serious adverse events include severe hypotension, pulmonary edema, and significant bleeding. Patients should be monitored closely for sudden drops in blood pressure, respiratory distress, or signs of hemorrhage, and treatment should be stopped immediately if these occur.

Iloprost is contraindicated in patients with uncontrolled hypotension, recent myocardial infarction, active severe infection, or known hypersensitivity to prostacyclin analogs. Caution is also advised for individuals with severe hepatic or renal impairment until safety is established.